Condition: Seizures · Lennox Gastaut Syndrome · Sponsor: SK Life Science, Inc.
The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in pediatric and adult subjects (age 4-55 years) diagnosed with Lennox Gastaut Syndrome (LGS).
This description comes directly from the study's public registry record.
Barbara Remes · 201-421-3810 · bremes@sklsi.com
Always discuss trial participation with your own doctor first.
| Stanford University Hospital | Palo Alto, California, United States | Recruiting |
| University of Florida Health Science Center | Jacksonville, Florida, United States | Completed |
| AdventHealth | Orlando, Florida, United States | Completed |
| Pediatric Epilepsy and Neurology Specialists | Tampa, Florida, United States | Recruiting |
| University of South Florida | Tampa, Florida, United States | Completed |
| Axcess Medical Research | Wellington, Florida, United States | Completed |
| Consultants in Epilepsy and Neurology PLLC | Boise, Idaho, United States | Completed |
| Bluegrass Epilepsy Research, LLC | Lexington, Kentucky, United States | Completed |
| University Medical Center New Orleans | New Orleans, Louisiana, United States | Completed |
| Johns Hopkins Hospital | Baltimore, Maryland, United States | Recruiting |
| Mid-Atlantic Epilepsy and Sleep Center | Bethesda, Maryland, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Completed |
+ 59 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05219617